Anika Therapeutics, Inc. — Q1 2012 Form 10-Q Summary
Business context and reporting period
Anika develops, manufactures, and commercializes hyaluronic-acid-based products for tissue protection, healing, and repair across orthobiologics, dermal, ophthalmic, surgical, and veterinary markets. This unaudited report covers the three months ended March 31, 2012, compared with the corresponding 2011 period. The company reported one operating segment.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Total revenue | $14.36 million | $11.74 million | 22% |
| Product revenue | $13.61 million | $11.06 million | 23% |
| Product gross profit | $7.20 million | $5.46 million | 32% |
| Product gross margin | 53% | 49% | +4 percentage points |
| Income from operations | $3.06 million | $0.56 million | 450% |
| Net income | $1.91 million | $0.32 million | 489% |
| Diluted earnings per share | $0.14 | $0.02 | Increase |
| Operating cash flow | $(1.69) million | $1.29 million | Decline |
Total operating margin increased to approximately 21.3% from 4.7%, while net margin increased to approximately 13.3% from 2.8%. Licensing, milestone, and contract revenue was $0.75 million, compared with $0.68 million.
- Orthobiologics revenue increased 26% to $10.12 million, led by ORTHOVISC and MONOVISC.
- Ophthalmic revenue increased 47% to $1.32 million, primarily from higher Bausch & Lomb orders.
- Veterinary revenue increased 62% to $0.69 million, primarily due to distributor order timing.
- Dermal revenue decreased 15% to $0.50 million, and surgical revenue decreased 12% to $0.98 million.
- Research and development expense was essentially unchanged at $1.53 million. Selling, general, and administrative expense decreased 17% to $3.35 million.
- Cash and cash equivalents were $34.0 million at March 31, 2012, versus $35.8 million at December 31, 2011. Working capital was approximately $51.1 million, compared with $49.6 million at year-end.
- Total debt was $10.8 million, including $1.6 million current and $9.2 million long term, at a reported interest rate of 1.72%. The term loan requires quarterly principal payments of $0.4 million and has a final $5.2 million installment due December 31, 2015.
- Capital expenditures were $0.22 million. Cash used in operations primarily reflected higher inventory and working-capital requirements associated with the Woburn facility closure and manufacturing transition.
Material changes versus the prior comparable period
- Revenue growth and improved product mix drove a substantial improvement in operating and net income.
- Q1 2011 revenue and gross margin were adversely affected by a Woburn equipment problem that delayed approximately $1.4 million of shipments and caused an approximately $0.45 million inventory write-down.
- SG&A declined because previously unoccupied Bedford facility space was placed in service rather than expensed.
- Operating cash flow shifted from positive to negative as inventory increased and working-capital needs rose.
- The company entered into a new three-year Bausch & Lomb supply contract effective January 1, 2012. Anika remains a second supplier, with committed 2012 volumes and lower commitments in 2013 and 2014.
- Anika entered into a new Italian distributor agreement; the transition reduced Italian revenue during the quarter. Italian accounts receivable totaled approximately $3.2 million, including approximately $2.4 million from public hospitals and government-funded agencies.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects 2012 joint-health revenue to increase from 2011 levels, while ophthalmic revenue is expected to be slightly lower and HYVISC revenue roughly comparable to 2011.
- Management expects research and development spending to increase as clinical work advances for Hyalograft C, CINGAL, and other pipeline programs. A multi-country, multi-year Hyalograft C clinical trial was planned to begin in September 2012.
- The company expects to transfer certain Anika S.r.l. manufacturing activities to Bedford beginning with ACP gel products in the second half of 2012. The transition is expected to benefit gross margin but increase annual depreciation expense by approximately $1.5 million once applicable Bedford approvals and production transfers occur.
- FDA approvals for Bedford aseptic manufacturing were obtained for all applicable products except AmVisc and AmVisc Plus; approval for those products was expected by the third quarter of 2012.
- MONOVISC remains subject to U.S. FDA approval and an ongoing appeal process. Genzyme litigation alleges patent infringement relating to MONOVISC; management believes losses are not probable and has recorded no accrual. DePuy Mitek agreed to assume certain related obligations under a December 2011 agreement.
- Merogel Injectable was withdrawn in 2011 because of a labeling error. Potential disputes with Medtronic and Fidia remain unresolved; management determined that contingent losses were not probable and recorded no accrual.
- Key risks include regulatory approvals, clinical-trial execution, intellectual-property disputes, product commercialization, dependence on distributors and strategic partners, manufacturing transfers, healthcare cost controls, foreign currency exposure, and variable-rate debt.
- Management stated that existing cash and other financial resources should support the business for the foreseeable future, but additional financing could be required if internal resources become insufficient.
Important facts for investors to verify
- Whether the strong Q1 revenue growth is sustainable after adjusting for the unfavorable comparison caused by the Q1 2011 Woburn disruption and for distributor order timing.
- Progress and costs associated with the Bedford manufacturing transition, including FDA approval for AmVisc and AmVisc Plus and the expected depreciation increase.
- The status and potential financial impact of the MONOVISC FDA appeal and Genzyme patent litigation.
- The resolution of the Medtronic and Fidia disputes related to Merogel Injectable and escrowed shares.
- Whether increased inventory and negative operating cash flow in Q1 are temporary or indicate continuing working-capital pressure.
- The expected reduction in Bausch & Lomb volumes after 2012 and the company’s ability to offset that impact.
- Execution of planned clinical programs, including Hyalograft C and CINGAL, and the resulting effect on research and development spending.